The clinical challenge of imatinib resistance in chronic myeloid leukemia: Emerging strategies with new targeted agents

Elias Jabbour, Jorge Cortes, Francis Giles, Susan O'Brien, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The disease is characterized by the presence of the Philadelphia chromosome, which arises following a balanced translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation (allo-SCT), which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) represented a major advance over conventional CML therapy. Following IM treatment, more than 90% of patients obtain complete hematologic response, and 70-80% of patients achieve a complete cytogenetic response. Resistance to IM represents an increasing clinical challenge and is often a result of point mutations causing a conformation change in Bcr-Abl, which impair IM binding. Novel targeted agents designed to overcome IM resistance, including multitargeted TKIs and farnesyl transferase inhibitors, are in various phases of development. Dasatinib, which has recently become available in the clinic, is a Bcr-Abl TKI that also inhibits Src, c-Kit, platelet-derived growth factor receptor, and ephrin A receptor kinases. In a phase II randomized trial in patients resistant or intolerant to IM, patients receiving dasatinib had better hematologic and cytogenetic responses than those on high-dose IM, irrespective of the presence or absence of mutations. Nilotinib has also shown promising activity. Combining IM with conventional chemotherapy, interferon, and targeted agents including TKIs is being actively pursued. Diagnostic testing may enable individualized targeted treatment so that patients receive the most effective agent first-line.

Original languageEnglish (US)
Pages (from-to)186-196
Number of pages11
JournalTargeted Oncology
Volume1
Issue number4
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
bcr-abl Fusion Proteins
Cytogenetics
Eph Family Receptors
Platelet-Derived Growth Factor Receptors
Chromosomes, Human, Pair 22
Philadelphia Chromosome
Chromosomes, Human, Pair 9
Imatinib Mesylate
Gene Fusion
Stem Cell Transplantation
Hematologic Neoplasms
Transferases
Point Mutation
Interferons
Phosphotransferases
Therapeutics
Drug Therapy
Mutation

Keywords

  • Bcr-Abl
  • CML
  • Dasatinib
  • Imatinib
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

The clinical challenge of imatinib resistance in chronic myeloid leukemia : Emerging strategies with new targeted agents. / Jabbour, Elias; Cortes, Jorge; Giles, Francis; O'Brien, Susan; Kantarjian, Hagop.

In: Targeted Oncology, Vol. 1, No. 4, 01.10.2006, p. 186-196.

Research output: Contribution to journalReview article

Jabbour, Elias ; Cortes, Jorge ; Giles, Francis ; O'Brien, Susan ; Kantarjian, Hagop. / The clinical challenge of imatinib resistance in chronic myeloid leukemia : Emerging strategies with new targeted agents. In: Targeted Oncology. 2006 ; Vol. 1, No. 4. pp. 186-196.
@article{904610cad58344058d4e1875065482b1,
title = "The clinical challenge of imatinib resistance in chronic myeloid leukemia: Emerging strategies with new targeted agents",
abstract = "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The disease is characterized by the presence of the Philadelphia chromosome, which arises following a balanced translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation (allo-SCT), which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) represented a major advance over conventional CML therapy. Following IM treatment, more than 90{\%} of patients obtain complete hematologic response, and 70-80{\%} of patients achieve a complete cytogenetic response. Resistance to IM represents an increasing clinical challenge and is often a result of point mutations causing a conformation change in Bcr-Abl, which impair IM binding. Novel targeted agents designed to overcome IM resistance, including multitargeted TKIs and farnesyl transferase inhibitors, are in various phases of development. Dasatinib, which has recently become available in the clinic, is a Bcr-Abl TKI that also inhibits Src, c-Kit, platelet-derived growth factor receptor, and ephrin A receptor kinases. In a phase II randomized trial in patients resistant or intolerant to IM, patients receiving dasatinib had better hematologic and cytogenetic responses than those on high-dose IM, irrespective of the presence or absence of mutations. Nilotinib has also shown promising activity. Combining IM with conventional chemotherapy, interferon, and targeted agents including TKIs is being actively pursued. Diagnostic testing may enable individualized targeted treatment so that patients receive the most effective agent first-line.",
keywords = "Bcr-Abl, CML, Dasatinib, Imatinib, Resistance",
author = "Elias Jabbour and Jorge Cortes and Francis Giles and Susan O'Brien and Hagop Kantarjian",
year = "2006",
month = "10",
day = "1",
doi = "10.1007/s11523-006-0032-3",
language = "English (US)",
volume = "1",
pages = "186--196",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - The clinical challenge of imatinib resistance in chronic myeloid leukemia

T2 - Emerging strategies with new targeted agents

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Giles, Francis

AU - O'Brien, Susan

AU - Kantarjian, Hagop

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The disease is characterized by the presence of the Philadelphia chromosome, which arises following a balanced translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation (allo-SCT), which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) represented a major advance over conventional CML therapy. Following IM treatment, more than 90% of patients obtain complete hematologic response, and 70-80% of patients achieve a complete cytogenetic response. Resistance to IM represents an increasing clinical challenge and is often a result of point mutations causing a conformation change in Bcr-Abl, which impair IM binding. Novel targeted agents designed to overcome IM resistance, including multitargeted TKIs and farnesyl transferase inhibitors, are in various phases of development. Dasatinib, which has recently become available in the clinic, is a Bcr-Abl TKI that also inhibits Src, c-Kit, platelet-derived growth factor receptor, and ephrin A receptor kinases. In a phase II randomized trial in patients resistant or intolerant to IM, patients receiving dasatinib had better hematologic and cytogenetic responses than those on high-dose IM, irrespective of the presence or absence of mutations. Nilotinib has also shown promising activity. Combining IM with conventional chemotherapy, interferon, and targeted agents including TKIs is being actively pursued. Diagnostic testing may enable individualized targeted treatment so that patients receive the most effective agent first-line.

AB - Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The disease is characterized by the presence of the Philadelphia chromosome, which arises following a balanced translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation (allo-SCT), which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) represented a major advance over conventional CML therapy. Following IM treatment, more than 90% of patients obtain complete hematologic response, and 70-80% of patients achieve a complete cytogenetic response. Resistance to IM represents an increasing clinical challenge and is often a result of point mutations causing a conformation change in Bcr-Abl, which impair IM binding. Novel targeted agents designed to overcome IM resistance, including multitargeted TKIs and farnesyl transferase inhibitors, are in various phases of development. Dasatinib, which has recently become available in the clinic, is a Bcr-Abl TKI that also inhibits Src, c-Kit, platelet-derived growth factor receptor, and ephrin A receptor kinases. In a phase II randomized trial in patients resistant or intolerant to IM, patients receiving dasatinib had better hematologic and cytogenetic responses than those on high-dose IM, irrespective of the presence or absence of mutations. Nilotinib has also shown promising activity. Combining IM with conventional chemotherapy, interferon, and targeted agents including TKIs is being actively pursued. Diagnostic testing may enable individualized targeted treatment so that patients receive the most effective agent first-line.

KW - Bcr-Abl

KW - CML

KW - Dasatinib

KW - Imatinib

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=33750035763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750035763&partnerID=8YFLogxK

U2 - 10.1007/s11523-006-0032-3

DO - 10.1007/s11523-006-0032-3

M3 - Review article

AN - SCOPUS:33750035763

VL - 1

SP - 186

EP - 196

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -